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ABSTRACT
Aims Anabolic–androgenic steroids (AAS) are widely used illicitly to gain muscle and lose body fat. Here we review
the accumulating human and animal evidence showing that AAS may cause a distinct dependence syndrome, often
associated with adverse psychiatric and medical effects. Method We present an illustrative case of AAS dependence,
followed by a summary of the human and animal literature on this topic, based on publications known to us or
obtained by searching the PubMed database. Results About 30% of AAS users appear to develop a dependence
syndrome, characterized by chronic AAS use despite adverse effects on physical, psychosocial or occupational func-
tioning. AAS dependence shares many features with classical drug dependence. For example, hamsters will self-
administer AAS, even to the point of death, and both humans and animals exhibit a well-documented AAS withdrawal
syndrome, mediated by neuroendocrine and cortical neurotransmitter systems. AAS dependence may particularly
involve opioidergic mechanisms. However, AAS differ from classical drugs in that they produce little immediate reward
of acute intoxication, but instead a delayed effect of muscle gains. Thus standard diagnostic criteria for substance
dependence, usually crafted for acutely intoxicating drugs, must be adapted slightly for cumulatively acting drugs such
as AAS. Conclusions AAS dependence is a valid diagnostic entity, and probably a growing public health problem.
AAS dependence may share brain mechanisms with other forms of substance dependence, especially opioid depen-
dence. Future studies are needed to characterize AAS dependence more clearly, identify risk factors for this syndrome
and develop treatment strategies.
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INTRODUCTION
The anabolic–androgenic steroids (AAS) are a family
of lipophilic hormones derived from cholesterol that
includes the natural male hormone, testosterone,
together with numerous synthetic testosterone deriva-
tives [1]. By ingesting supraphysiological doses of these
hormones, in combination with intensive weightlifting
and appropriate nutrition, AAS users can greatly
increase their muscle mass, often well beyond the limits
attainable by natural means [2]. For decades, elite ath-
letes have used AAS to improve performance [3]. Today,
however, most AAS users are not competitive athletes,
but simply individuals who want to look leaner and more
muscular [1,4–8]. As we have explained in detail else-
where [9], this much larger but less visible population of
illicit AAS users began to emerge in the 1980s—a trend
stimulated in part by the appearance of progressively
more sophisticated underground guides on how to self-
administer AAS [10–14]. Western cultural developments
also probably contributed to the increased prevalence
of use of AAS, as media images focused increasingly on
male muscularity [15–18]. Over the last few decades,
even children’s action toys, such as ‘GI Joe’ in America
and ‘Action Man’ in the British Commonwealth, have
begun to acquire the bodies of AAS users [19]. Perhaps as
a result of these trends, illicit AAS use has now grown
into a widespread form of substance abuse throughout
western societies, including the United States [20–22],
British Commonwealth countries [23–25], Scandinavian
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countries [26–28] and others [25,29–31]. Although epi-
demiological studies in these various countries have pro-
duced a wide range of prevalence estimates, most have
reported a life-time prevalence of AAS use of at least 3%
in young men, suggesting that some tens of millions
of individuals world-wide have used these drugs. By con-
trast, AAS use in women is uncommon, as women are
less likely to want to become very muscular and are also
vulnerable to the masculinizing effects of AAS, such as
beard growth, deepening of the voice and masculinized
sexual characteristics [32–35].
AAS users generally self-administer their drugs for
blocks of time, called colloquially ‘cycles’. Cycles typically
last 8–16 weeks, separated by drug-free intervals lasting
months or years [36,37]. Planned cycles of increasing
and decreasing AAS doses (‘pyramiding’) allow users to
avoid plateauing (developing tolerance), minimize with-
drawal symptoms at the end of a cycle and conserve drug
supplies [38]. Perhaps the most important rationale for
cycles, however, is the fact that exogenous AAS adminis-
tration suppresses the hypothalamic–pituitary–testicular
(HPT) axis, leading to decreased endogenous testosterone
production in men [39,40]. If a man uses AAS in cycles,
rather than continuously, then the HPT axis can rebound
during the drug-free intervals between cycles, restoring
normal endogenous testosterone production.
Many individuals use only a few cycles of AAS in their
careers, with a cumulative life-time exposure of less than
12 months [36,37]. Such individuals often report few, if
any, adverse medical or psychological effects from AAS
[41,42]. On the other hand, some individuals progress
from discrete cycles of AAS into a pattern of nearly
unbroken use, which may continue despite prominent
adverse medical, psychological and social effects [43].
This syndrome of AAS dependence has been recognized
for more than 20 years; it appears to be common and
possibly increasing in prevalence, as explained below, but
much in need of further study [1]. Here we attempt to
summarize current knowledge on AAS dependence. We
begin with an illustrative case of AAS dependence, then
review the accumulating human and animal literature
on this topic, compare AAS dependence with classical
drug dependence and suggest avenues for future
research. This review is based on publications known to
us, a search of publications involving ‘anabolic steroids’
in the PubMed database and additional publications ref-
erenced in these articles.
CASE EXAMPLE
Mr A, currently 34 years old, grew up in an upper-
middle-class professional family in South Florida. He
reported no major social or academic problems prior to
adolescence, but by age 17 developed alcohol and nico-
tine dependence, soon followed by polysubstance depen-
dence involving marijuana, hallucinogens, alcohol and
cocaine, depending on which drugs were available. At
age 19 he was admitted to a detoxification facility, and
thereafter remained abstinent from ‘classical’ drugs of
abuse for the next 3 years. During this period, however,
he began regular weightlifting in the gym, acquired
AAS-using friends, and soon began to use AAS himself,
starting with cycles of 12–16 weeks in duration, sepa-
rated by drug-free intervals of 4–8 weeks. Like his AAS-
using friends, Mr A became focused on his muscularity
and often felt that he was still not big enough, despite
his objective gains. He increased his doses of AAS over
the next several years, reaching a maximum weekly
dose of 500 mg of injectable testosterone esters, com-
bined with 400 mg of injected nandrolone decanoate,
plus 50 mg of oral methenolone per day—a total dose
equivalent to more than 20 times normal male endog-
enous testosterone production [44]. He gained some
25 kg of muscle over the course of the first 2 years;
during this time he reported increased self-confidence
and mild irritability, but no major adverse psychiatric or
medical effects.
At age 22, Mr A relapsed into use of classical drugs
and developed opioid and cocaine dependence, reaching
doses of 300 mg of OxyContin (long-acting oxycodone)
per day. He continued to take AAS intermittently during
this period. He underwent three detoxification admissions
for opioid dependence over the next 4 years, and stopped
using all classical drugs of abuse (including alcohol)
successfully by age 26. By the age of 32, he also stopped
smoking cigarettes. However, he has continued to use
AAS steadily from age 26 to the present. During the first
part of this interval Mr A still discontinued AAS for
several weeks between cycles, but since age 31 he has
been taking AAS virtually without interruption. He
reports that if he stops using AAS, he quickly develops
prominent fatigue, loss of sex drive and depressed mood.
Therefore, he maintains carefully a sufficient supply of
AAS to allow uninterrupted use.
Mr A now uses lower doses of AAS than when
younger, with an average weekly dose of about 400–
600 mg of testosterone or equivalent. He currently
displays several apparent adverse AAS effects, includ-
ing bilateral gynecomastia and a recent fasting total
cholesterol/high-density lipoprotein (HDL) ratio of 18.6
(normal less than 5.0). Mr A expresses concern about
these effects, but is reluctant to discontinue or reduce
AAS because he fears ‘losing size’. He spends several
hours per day at the gym, where he has many friends,
most of whom are also AAS users. He has worked as a
personal trainer for some time in a local health club, then
at a store selling sports supplements such as protein
powders and creatine. His life remains centered around
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the gym and the weightlifting culture, often to the exclu-
sion of other social or occupational opportunities.
HUMAN STUDIES
Initial reports and case series, 1988–1990
Mr A’s history resembles that of other cases of AAS
dependence reported previously. This literature began to
appear in the late 1980s, starting with individual case
reports describing AAS users who took the drugs initially
to gain muscle for bodybuilding, but who went on to
develop depression whenever they discontinued AAS use
[45–47]. Interestingly, one of these individuals exhibited
symptoms resembling opiate withdrawal when chal-
lenged with naloxone, although he had no apparent
history of opiate use—an observation suggesting that
AAS dependence might be associated with opioid-type
features [45]. In the first published case series, Brower
et al. [48] described eight AAS users with apparent
dependence; all these men met two of the DSM-III-R
criteria [49] for substance dependence, summarized as
‘continued substance use despite problems caused or
worsened by use’ and ‘withdrawal symptoms’. However,
users varied with regard to the other DSM-III-R substance
dependence criteria, many of which were designed for
acutely intoxicating drugs, and which were therefore not
well suited for drugs such as AAS that produce little acute
intoxication.
Studies using DSM-III-R and DSM-IV criteria,
1991–2005
Several subsequent studies in the United States, United
Kingdom and Australia ([50–54]; Table 1) have also
attempted to diagnose AAS dependence using the DSM-
III-R [49] or DSM-IV [55] criteria for substance depen-
dence, despite the difficulties of adapting these criteria to
a non-intoxicating drug. Of 426 AAS users across these
five studies, 144 (33.8%) met DSM-IV criteria for depen-
dence, as the study authors interpreted these criteria for
the case of AAS. As in the case series above, withdrawal
was the criterion met most commonly, whereas ‘frequent
intoxication or withdrawal symptoms when expected to
function’ was rare, as might be expected. A sixth study,
using the Structured Clinical Interview for DSM-III-R
(SCID) [56], reported dependence in 10 (14%) of 71
current or past male AAS users and one (17%) of six
female AAS users ([57] and D. A. Malone, personal com-
munication, January 2009). Finally, a seventh study, also
using the SCID, reported a life-time history of AAS depen-
dence in approximately 22 (25%) of 88 male AAS users
[37]. However, these latter two studies did not specify the
number of AAS users meeting each individual DSM-IV
substance dependence criterion in the manner of the
studies summarized in Table 1.
It should be recognized that the above studies are
naturalistic studies of AAS users recruited in the field
from gymnasiums [37,50–53,57] or via the internet
[54]. Like all naturalistic studies of illicit substance
abusers, these studies are potentially vulnerable to
various forms of bias [58,59]. For example, dependent
AAS users may have been either more or less likely to
agree to participate in these studies than non-dependent
AAS users or AAS non-users, resulting in selection bias.
Information bias may have resulted if respondents failed
to disclose that they had used AAS, or failed to report
adverse or undesirable outcomes associated with AAS
use. Confounding variables, such as premorbid attri-
butes of AAS users or concomitant use of other sub-
stances, may have also influenced observed associations.
However, because human AAS dependence cannot,
ethically, be studied prospectively under laboratory con-
ditions, these field studies currently represent our best
available evidence regarding this syndrome.
The prevalence of AAS dependence
Collectively, the above seven studies suggest that about
30% of illicit AAS users develop dependence—although
it must be remembered that this estimate might be influ-
enced by selection bias. For example, individuals who
had experimented only briefly with AAS might be under-
represented in samples recruited from gymnasiums,
causing the studies to overestimate the prevalence of
AAS dependence. In any event, however, there is reason
to suspect that the prevalence of clinically significant
AAS dependence may be increasing. This impression is
based on the observation that the mean age of onset
of AAS dependence in the above studies appears to be in
the late 20s. Therefore, adverse psychiatric and medical
effects of prolonged AAS dependence would probably not
surface until age 30 or later [1,9]. When it is considered
that illicit AAS use did not become widespread until the
1980s, as discussed above, it follows that within the
subgroup of AAS users who have developed chronic
use, many are only now growing old enough to show
clinically significant AAS dependence. Therefore, as
new waves of recent younger AAS users reach their
30s and 40s, the prevalence of AAS dependence may
continue to rise.
We can illustrate the above considerations using
prevalence data on male AAS users in the United States.
American surveys over the last 20 years have estimated
that 3–11% of male high school students have used AAS
[5,21,60–64]. We have suggested elsewhere that some of
these estimates may be too high [35]—but even using the
lowest figure of 3%, it would follow that over the last 20
1968 Gen Kanayama et al.
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years, more than 1 million American boys initiated AAS
use as teenagers. Furthermore, as the median age of
onset of initial AAS use in the United States appears to be
considerably older than age 19 [35,36], one must add to
this figure at least another million American men in the
last two decades who first initiated AAS use after the age
of 19. About half of this 20-year cohort of American
AAS users is still under age 30 today. If we estimated
conservatively that the risk of AAS dependence among
these men was only 14%—the lowest figure reported
among the seven studies above—it would still follow that
in the United States alone there are hundreds of thou-
sands of still-young chronic AAS users who are only now
approaching the age where they may show clinically sig-
nificant AAS dependence. Chronologically, most other
western countries probably lag the United States in the
onset of widespread AAS use—placing them earlier on
this possible curve of rising AAS dependence.
Features of AAS dependence
Despite the substantial prevalence of AAS dependence,
little is known about the features of AAS-dependent indi-
viduals. Several studies have noted that dependent users
consumed significantly more AAS than non-dependent
users, as measured by total dose [50], number of different
AAS taken simultaneously [53], total number or length
of AAS cycles [50,51,54] or cumulative duration of AAS
use [53]. When demographic correlates of dependent use
were assessed [50,51], however, no differences between
dependent and non-dependent users were found. Two
studies reported a significantly greater likelihood of
either aggressive symptoms [50] or ‘roid rage’ [51] in
dependent versus non-dependent users. However, none of
the studies in Table 1 assessed life-time psychiatric disor-
ders systematically in user groups.
One new study has recently assessed demographic
variables and life-time psychiatric disorders in men with
AAS dependence (n = 20) compared to non-dependent
AAS users (n = 42) and AAS non-users (n = 72) [8]. In
this study, non-dependent AAS users exhibited virtually
no significant differences from non-users on any of a wide
range of demographic variables or life-time psychiatric
diagnoses, whereas the dependent AAS users differed
markedly from both comparison groups on a number of
measures. Specifically, dependent AAS users were signifi-
cantly older and more muscular than the other groups;
more likely to have had a single parent by age 13; more
likely to report a first-degree relative with a substance use
disorder; and less well educated. Dependent AAS users
also reported a much more frequent history of conduct
disorder than non-dependent AAS users and a much
higher life-time prevalence of non-alcohol substance
dependence than either comparison group; the latter dif-
ferences were driven largely by a strikingly higher preva-
lence of opioid abuse and dependence—an important
finding that we discuss in more detail in the following
paragraphs.
The association of AAS dependence with
opioid dependence
Several reports have suggested that AAS dependence
might share features with opioid dependence in humans.
As early as 1989, Kashkin & Kleber hypothesized that
AAS dependence might arise in part via an opioidergic
mechanism, in which AAS might potentiate central
endogenous opioid activity and where AAS withdrawal
would lead to a decrease in this activity and a subsequent
acute hyperadrenergic syndrome [65]. This hypothesized
link between AAS and opioids would seem consistent with
a number of human observations including (i) the ‘opioid-
type features’ described in the case report of AAS depen-
dence cited above [45]; (ii) the observation that AAS users
seem to be particularly at risk for developing opioid abuse
or dependence [66–68]; (iii) the converse finding that men
with opioid dependence were more likely to report prior
AAS use than men with other forms of substance depen-
dence [69]; and (iv) a post-mortem study of Swedish AAS
users, reporting that AAS appeared to reduce the thresh-
old for heroin overdose [70].
The recent field study described above adds further
evidence for a relationship between AAS and opioids [8].
Ten (50%) of the dependent AAS users in this study met
DSM-IV criteria for a life-time history of opioid abuse or
dependence, compared to eight (19%) non-dependent
AAS users [odds ratio 6.7; (1.5, 231); P = 0.015] and five
(7%) non-users [16.3 (3.4, 78.9); P = 0.001]. Among
the various men with AAS dependence, opioid abuse
or dependence began both before and after the onset of
AAS use, suggesting the possibility that these forms of
substance use might arise from a common diathesis.
ANIMAL STUDIES
Animal studies offer extensive additional evidence that
AAS can induce dependence, and further support a link
between the actions of AAS and opioids [71]. In humans,
it is difficult to separate the direct rewarding effects of
AAS from the secondary rewards of increased muscular-
ity and fitness. However, using conditioned place prefer-
ence and self-administration models of reward, studies in
animals have demonstrated that AAS are rewarding in
a context where athletic performance is irrelevant. Rats
and mice will choose to spend time in an environment
where they have previously received AAS [72,73]. Ham-
sters will self-administer testosterone, including direct
intracranial injections to the point of death, and they
1970 Gen Kanayama et al.
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develop a syndrome of high-dose testosterone intoxi-
cation with opioid-like features [74]. Moreover, this
syndrome is antagonized by naltrexone, and naltrexone
pretreatment will prevent testosterone self-administra-
tion [75]. Not all animal species, however, appear to self-
administer AAS [76].
Animal studies also suggest that AAS modify brain
opioid systems. For example, chronic nandrolone treat-
ment in rats increased levels of endogenous opioids
and their receptors in select limbic regions, including a
20-fold increase in beta-endorphin in the ventral tegmen-
tal area [77], as well as a selective reduction in dynorphin
b in the nucleus accumbens [78]. Other studies in rats
[79] and mice [80] have also shown that AAS may act
by altering levels of opioid receptors. Actions of AAS to
inhibit activity of the dynorphin/kappa opioid receptor
system in the nucleus accumbens are particularly
intriguing. Treatment with kappa receptor antagonists in
the nucleus accumbens produces anxiolytic and antide-
pressant effects [81,82], similar to the effects of AAS [83].
The AAS-induced reduction in nucleus accumbens
dynorphin might also facilitate dopaminergic activity
[78]. However, it is notable that, unlike many other drugs
of abuse, AAS do not stimulate dopamine release acutely
in the nucleus accumbens [84]. This is consistent with
the relatively slow time–course of AAS action, and may
account for the absence of acute intoxicating effects.
Studies using the opioid antagonist naloxone have
yielded variable results in AAS-treated animals. Nan-
drolone pretreatment enhanced withdrawal symptoms
to naloxone in morphine-dependent mice [80], and
naloxone reversed testosterone-induced locomotor
depression in hamsters [75]. However, naloxone pro-
duced virtually no effects in three rhesus monkeys
exposed to 2 weeks of high-dose testosterone [85]. It may
be that testosterone serves as a partial opioid agonist,
while also acting through several other non-opioid
neurotransmitter systems. Specifically, AAS display
important modulatory effects on serotonin [86–92],
norepinephrine [89], dopamine [93–101] and gamma-
amino-butyric acid [93,100,102,103]. Animal studies
have also shown that AAS modulate the effects of other
drugs of abuse, such as central nervous system stimu-
lants [104], cannabis [105] and alcohol [78,87]. Finally,
androgen withdrawal is also probably a complex
phenomenon that shares multiple mechanisms with
other endocrine withdrawal syndromes and with with-
drawal from drugs of abuse—including changes in opioid
peptide systems, the mesolimbic dopaminergic system
and other central pathways [106]. Although a full discus-
sion of this literature is beyond the scope of the present
paper, several recent reviews have addressed in greater
detail the interactions of AAS with various neurotrans-
mitter systems and with other drugs [71,93,101].
AAS DEPENDENCE VERSUS ‘CLASSICAL’
DRUG DEPENDENCE
As illustrated in the above sections, AAS show both simi-
larities and differences when compared to classical drugs
of abuse (Table 2). Similarities include a characteristic
Table 2 Similarities and differences between anabolic–androgenic steroids (AAS) and classical drugs of abuse.
Classical drugs AAS
Similarities
Animals will self-administer many classical drugs Hamsters will self-administer AAS
Withdrawal syndrome after prolonged use of many drugs Characteristic withdrawal syndrome after prolonged use
Individuals often continue drug use despite adverse
medical and psychological effects
Use may be continued despite adverse effects
Distinct subculture surrounding use of the drug Well-established subculture involving the gym and body image
Polydrug use common AAS users frequently abuse other drugs
Differences
Immediate reward from intoxicating effect No immediate intoxication, but may cause increased energy,
libido, and self-confidence in addition to delayed muscular gains
Frequent residual adverse effects from intoxication
(hangovers, sleep disruption, acute withdrawal
depression, etc.)
Few immediate adverse effects
Frequently impairs performance (work, driving, etc.) Minimal performance impairment, although irritability, aggression,
and mood swings may impair social relationships
Physiological tolerance develops to many drugs Limited evidence for physiological tolerance, although users may
intentionally increase doses to increase effects
Time-consuming (obtaining drug, intoxication,
recovery from intoxication)
No acute intoxication, so that drug use per se is rarely
time-consuming
Anabolic-androgenic steroid dependence 1971
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withdrawal syndrome, self-administration by animals
as just discussed, continued use despite adverse effects,
maladaptive behavioral patterns surrounding use, and
comorbid abuse of other substances, as illustrated by the
case of Mr A and in various reports in the literature
[8,9,21,36,62,63,69,107–111]. Unlike classical drugs
of abuse, however, AAS produce no immediate reward in
the form of acute intoxication. In one study, for example,
abstinent heroin users could readily distinguish single
injections of morphine as rewarding, whereas injections
of testosterone or placebo were not perceived as reward-
ing [112]. Although AAS may produce some feelings of
euphoria and increased self-confidence, these effects are
inconsistent, slow to develop, and usually immaterial in
the decision to use the drugs [59]. Also, as they are
not acutely intoxicating, AAS rarely compromise perfor-
mance or cause acute adverse effects in the manner of
drugs such as cocaine or alcohol.
This fact may explain why individuals with AAS
dependence appear less likely to seek treatment than indi-
viduals with many forms of classical drug dependence,
who often seek treatment because of impaired occupa-
tional function, complaints from significant others or
subjective distress [113]. In addition, some data suggest
that AAS users may also be reluctant to seek treatment
because they distrust health professionals and doubt
that such professionals have sufficient knowledge of AAS
[114]. Several authors have commented on the need
for professionals to become more familiar with AAS in
response to these problems [113,115,116].
Given the slow time–course of AAS effects and the
absence of acute intoxication, standard substance-
dependence criteria, such as those of DSM-IV [55]
or ICD-10 [117], do not fit AAS dependence precisely,
because these criteria were generally crafted to apply pri-
marily to acutely intoxicating drugs. However, as illus-
trated in a recent publication (see Table 3), the DSM-IV
criteria can be adapted easily with minor modifications
to capture the maladaptive features of AAS dependence
[118].
It should be noted that nicotine dependence, like AAS
dependence, also differs from classical drug dependence,
because few users smoke tobacco for its acute intoxicat-
ing effects [119]. Indeed, in contrast to the other catego-
ries of substances, a diagnosis of nicotine intoxication
does not appear in DSM-IV. Unlike nicotine dependence,
however, which rarely impairs psychological or social
functioning, AAS dependence is similar to other drugs of
dependence in terms of its potential adverse behavioral
outcomes, such as impaired interpersonal functioning
and substance-induced mood disorders [43].
In the United States, most prescription drugs with
abuse potential are classed as Schedules II, III or IV sub-
stances under the jurisdiction of the Drug Enforcement
Table 3 DSM substance dependence criteria interpreted for
diagnosing anabolic–androgenic steroids (AAS) dependence
(from Kanayama et al. [118]).
A maladaptive pattern of anabolic–androgenic steroids (AAS) use,
leading to clinically significant impairment or distress, as
manifested by three (or more) of the following, occurring at any
time in the same 12-month period:
1 Tolerance, as defined by either of the following:
(a) a need for markedly increased amounts of the substance
to achieve intoxication or desired effect; for AAS this
progression to markedly larger doses may be related to
dissatisfaction with the previous level of desired effect (e.g.
level of muscle mass)
(b) markedly diminished effect with continued use of the same
amount of the substance (e.g. failure to maintain the same
level of lean muscle mass on a given dose of AAS)
2 Withdrawal, as manifested by either of the following:
(a) a characteristic withdrawal syndrome, characterized for
AAS by two or more of the following features: depressed
mood, prominent fatigue, insomnia or hypersomnia,
decreased appetite and loss of libido
(b) AAS are used to relieve or avoid withdrawal symptoms
3 The substance is often taken in larger amounts or over a
longer period than was intended. For AAS, this may be
manifested by repeatedly resuming courses of AAS use after
a shorter ‘off’ period than the individual had originally
planned, or by eliminating ‘off’ periods entirely
4 There is a persistent desire or unsuccessful efforts to cut
down or control substance use. For AAS, this may be
manifested by unsuccessful attempts to reduce or stop AAS
use because of prominent anxiety about losing perceived
muscular size
5 A great deal of time is spent in activities necessary to obtain
the substance, use the substance or recover from its effects.
For AAS, this may be manifested by extensive time spent
participating in muscle-related activities surrounding AAS
use (e.g. time spent in weight training, attending to diet and
supplement use and associating with other AAS users) in
addition to actual time spent obtaining and administering
AAS
6 Important social, occupational, or recreational activities are
given up or reduced because of substance use. For AAS, this
may be manifested by giving up important outside activities
because of an extreme preoccupation with maintaining a
supraphysiological AAS-induced level of muscularity (e.g.
the individual relinquishes outside activities for fear that
these activities will cause him to miss workouts, violate
dietary restrictions, or compromise his ability to use of AAS)
7 The substance use is continued despite knowledge of having
a persistent or recurrent physical or psychological problem
that is likely to have been caused or exacerbated by the
substance. For AAS, this includes medical problems such as
gynecomastia, sexual dysfunction, hypertension,
dyslipidemia and cardiomyopathy; or psychological problems
such as dysphoric mood swings, severe irritability or
increased aggressiveness
1972 Gen Kanayama et al.
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Administration [120]. AAS are presently classed in
Schedule III; interestingly, they represent the only class of
substances in Schedules II or III that is not already recog-
nized specifically in DSM-IV as causing a dependence
syndrome [118]. Unlike most other scheduled drugs,
however, AAS are available legally over the counter
in many countries, and they can be ordered easily over
the internet from overseas, making enforcement and
interdiction difficult in countries where AAS are illegal
[121].
WHAT CAUSES AAS DEPENDENCE?
In conclusion, why do some 30% of AAS users progress
from more benign casual AAS use to more chronic and
malignant AAS dependence, while 70% do not? Unfortu-
nately, as discussed above, current knowledge of human
AAS dependence remains limited—indeed, arguably
more limited than for any other major form of substance
dependence. However, several hypotheses deserve consid-
eration. First, the progression to AAS dependence might
be catalyzed by body image disorders such as ‘muscle
dysmorphia’ [17]—a form of body dysmorphic disorder,
sometimes called ‘reverse anorexia nervosa’, character-
ized by preoccupations that one does not look sufficiently
muscular [8,36,122–129]. Individuals with muscle dys-
morphia may develop a maladaptive pattern of chronic
AAS use because, paradoxically, they often become
increasingly dissatisfied with their muscularity despite
growing bigger on AAS [69,123]. However, this hypoth-
esis remains uncertain. In an analysis of preliminary
data from an ongoing study of AAS users conducted by
three of the present authors (see [8]), it appears that ado-
lescent body image disorder is associated strongly with
initiation of AAS use. However, among AAS users, those
who progressed to AAS dependence did not show a
greater level of body image disturbance than those who
did not. In other words, concerns about muscularity may
bring an individual to the threshold of initially using
AAS, but beyond this effect these concerns may not deter-
mine whether that individual progresses onward to AAS
dependence (G. Kanayama, J. I. Hudson & H. G. Pope Jr,
2009, unpublished data).
A second possible hypothesis is that individuals who
progress to AAS dependence are more biologically vul-
nerable to the dysphoric effects of AAS withdrawal. As
noted, AAS produce a characteristic withdrawal syn-
drome, with both affective and hypogonadal symptoms
[65,130–132]. Individuals with more severe withdrawal
symptoms after initial cycles of AAS use might become
increasingly prone to resume AAS to prevent these symp-
toms. As implied above, this possible biological vulner-
ability might be related to the HPT axis, to opioidergic
pathways or to other neurotransmitter mechanisms.
A third possible hypothesis is suggested by the appar-
ent overlap of AAS dependence with other forms of
substance dependence and with conduct disorder. An
evolving neuropsychological literature has shown that
individuals with many other forms of substance depen-
dence exhibit a cluster of cognitive attributes that might
be summarized as ‘risk-taking/decision-making deficits’,
such as elevated rates of delay discounting [133,134];
increased impulsivity [135–137]; and deficits in decision-
making, as illustrated by performance on gambling tasks
and other measures of risk-taking [135,138–140]. These
deficits are also associated with antisocial or ‘psycho-
pathic’ traits [141–144], including conduct disorder
[145–147]. Conduct disorder in turn appears to be asso-
ciated with AAS dependence [8], and other studies have
documented criminality and so-called Cluster B person-
ality traits, including antisocial personality, among AAS
users [121,148–155]. These features may, collectively,
mark an endophenotype [156] that plays a causal role in
the development of substance dependence [135]. With
AAS, the direction of causality might well go both ways:
in individuals with these hypothesized underlying defi-
cits, use of testosterone and presumably other AAS may
shift the balance even further towards an increased sen-
sitivity for reward and decreased sensitivity for threat or
punishment, as suggested by both animal [157,158] and
human studies [159,160]. No studies, to our knowledge,
have assessed the possible role of such deficits in individu-
als with AAS dependence, but this possibility would seem
to deserve further investigation.
CONCLUSIONS
A growing literature of human and animal studies sug-
gests that AAS dependence is a valid diagnostic entity,
often associated with conduct disorder and other forms
of substance abuse. The prevalence of AAS dependence
may be rising, as increasing numbers of AAS users are
growing old enough to have established a dependence
pattern. The diagnosis of AAS dependence requires
some modest adaptations of standard diagnostic criteria
for substance dependence, because these criteria were
designed primarily for acutely intoxicating drugs and are
not suited optimally for cumulatively acting drugs such
as AAS. However, as suggested above, such criteria can be
adapted easily for the diagnosis of AAS dependence.
AAS dependence is arguably the only major form of
world-wide substance dependence that remains largely
unexplored. In particular, it remains unclear why some
AAS users progress from more benign initial use to more
malignant AAS dependence—and the observed overlap
between AAS and opioids, in both men and animals,
might possibly hold a key to this explanation. Under-
standing the nature and etiology of AAS dependence is a
Anabolic-androgenic steroid dependence 1973
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matter of growing public health importance, as indivi-
duals with dependence probably account for the great
majority of the public health problems associated with
AAS, including the cardiovascular, neuroendocrine and
psychiatric complications of long-term AAS exposure [9].
With an improved understanding of AAS dependence, we
may be able to identify more clearly those at risk and
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